<table>
<thead>
<tr>
<th>CONTENTS</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>5</td>
</tr>
<tr>
<td>Board of Directors</td>
<td>7</td>
</tr>
<tr>
<td>Scientific and Medical Panel</td>
<td>10</td>
</tr>
<tr>
<td>Chairman’s Report</td>
<td>12</td>
</tr>
<tr>
<td>Company Secretary’s Report</td>
<td>13</td>
</tr>
<tr>
<td>A Year in Review: Fundraising</td>
<td>14</td>
</tr>
<tr>
<td>A Year in Review:</td>
<td>18</td>
</tr>
<tr>
<td>Consumer Dementia Research Network</td>
<td></td>
</tr>
<tr>
<td>2011 Dementia Grants Program Summary</td>
<td>19</td>
</tr>
<tr>
<td>The Hazel Hawke Alzheimer’s Research and Care Fund</td>
<td>20</td>
</tr>
<tr>
<td>Alzheimer’s Australia Dementia Research Foundation Research Grants</td>
<td>22</td>
</tr>
<tr>
<td>Alzheimer’s Australia Dementia Research Foundation Victoria Grants</td>
<td>26</td>
</tr>
<tr>
<td>Postdoctoral Fellowship Awards</td>
<td>28</td>
</tr>
<tr>
<td>Postgraduate Scholarships</td>
<td>30</td>
</tr>
<tr>
<td>Resthaven Inc. 75th Anniversary Postgraduate Scholarship</td>
<td>34</td>
</tr>
<tr>
<td>Rosemary Foundation Travel Awards</td>
<td>36</td>
</tr>
<tr>
<td>2012 Dementia Grants Program</td>
<td>38</td>
</tr>
<tr>
<td>Thank You for Your Support</td>
<td>40</td>
</tr>
<tr>
<td>Financial Report</td>
<td>43</td>
</tr>
</tbody>
</table>
INTRODUCTION

Alzheimer’s Australia Research now goes by the new name of Alzheimer’s Australia Dementia Research Foundation. We changed our name to reflect our purpose better: to fund research into all forms of dementia.

Who we are
Alzheimer’s Australia Dementia Research Foundation is the research arm of Alzheimer’s Australia. We support and fund research to help people living with dementia and their families, as well as research to develop new treatments for the future. From improvements in diagnosis, management and care to prevention and delay of dementia, we support new researchers in their fight against this devastating condition. We believe science holds the key to defeating dementia.

What we do
- We invest in Australia’s most talented new and early career dementia researchers.
- We support innovative Australian research that offers the best hope of defeating dementia.
- We work with people with dementia to ensure that research reflects their concerns.
- We fund world-class research into the prevention, treatment and cure for dementia.
- We help people understand dementia and the progress research is making.
- We aim to make dementia a national research priority.

How we do it
Australia has some of the top dementia researchers in the world. These researchers are dedicated to finding better treatments for dementia and improving the quality of dementia care.

We are dedicated to supporting them.

The annual Dementia Grants Program provided competitive research funding worth more than $1 million in 2011. The program included research project grants, travel grants, postgraduate scholarships and postdoctoral fellowships. All of the funding for the Dementia Grants Program is donated by members of the public and by private and philanthropic organisations. Some of our many supporters are featured in this report. We hope you enjoy their stories.

Why is dementia research important?
Dementia is currently the third leading cause of death in Australia, and without new treatments or interventions, the number of people with dementia will soar. At the moment, dementia touches almost 1.5 million of us, including over 300,000 Australians with dementia and a further 1.2 million people providing support and care. Between 2012 and 2050, it is estimated that over 3 million Australians will develop dementia.

There are currently no effective ways to halt or reverse the damage caused by dementia, and while there are simple lifestyle modifications that anyone can use to reduce their risk, investment in research is the only way in which we can hope to beat this condition.

Dementia research is critical both to reduce the number of people living with the condition in the future, and to ensure that people with dementia have a better quality of life now.

Australian scientists are working hard to find better ways to delay, prevent and ultimately cure dementia and they have already made great progress in identifying those most at risk, and establishing the beneficial effects of a healthy lifestyle in reducing that risk. But there is still a long way to go.

That is why the Alzheimer’s Australia Dementia Research Foundation is focused on helping new researchers establish their careers and become the next leaders in their field.

The funding we offer is approaching 10 per cent of what the Federal Government invests in dementia research through the National Health and Medical Research Council, and is performing the vital role of building capacity for the dementia research effort needed to change the future.
Scientia Professor Henry Brodaty AO, Chairman
Professor Henry Brodaty is Scientia Professor of Ageing and Mental Health and Director of the Dementia Collaborative Research Centre at the University of New South Wales. He is also the Director of Aged Care Psychiatry and head of the Memory Disorders Clinic at the Prince of Wales Hospital. Professor Brodaty has been Chairman of Alzheimer’s Disease International, president of Alzheimer’s Australia and Alzheimer’s Australia NSW and is President-Elect of the International Psychogeriatric Association. He has published extensively and is on the editorial board of several journals. Professor Brodaty is a member of several key State and National Committees concerned with dementia and mental health in older people and has received many awards, including an Officer of the Order of Australia in 2002.

Professor John McKellar AM ED, Vice Chairman
Professor John McKellar is currently a Director of the National Board of the Order of Australia Association and Chairman of the SA branch of the Association. He is also a Director and Secretary of the Rosemary Foundation. Professor McKellar was awarded Senior Australian of the Year for South Australia in 2001. He was also awarded Member of the Order of Australia in the Queen’s Birthday Honours list in 2008 for “Service to people with dementia, particularly Alzheimer’s disease, and their carers, through organisations that provide education, support services and funding for research.”

Gordon Robinson, Treasurer
Gordon Robinson has a business background with over 30 years in the consumer goods industry, including Australian and overseas CEO positions in South America and Europe. Gordon has been associated with Alzheimer’s Australia for the past 15 years as past Victorian President and National Vice President.

Glenn Rees, Company Secretary
Glenn Rees has worked at senior levels in the British and Australian public services. In Britain he worked as Private Secretary to senior Ministers in the Cabinet Office and in Economic Departments. Since 1976 he has worked in Australia in program and policy areas including; Prime Minister and Cabinet, Employment and Training, Aged Care, Disabilities, Housing and the Aboriginal and Torres Strait Islander Commission. He was Chair of the Nursing Homes and Hostels Review in 1986 and was involved in implementing the first wave of aged care reforms. Glenn has been Chief Executive Officer of Alzheimer’s Australia since 2000, during which time dementia has been made a National Health Priority Area.

Kaye Pritchard
Kaye Pritchard has been an active member of the Alzheimer’s Australia National Board and various committees to represent people living with dementia. Kaye’s passion since her husband was diagnosed with Frontotemporal dementia in 1998 is to help others to understand the issues of living with dementia.

Dr Robert Yeoh
Dr Robert Yeoh is a general practitioner with a special interest in dementia. He has been a member of the Board of Directors of Alzheimer’s Australia NSW since 1994, holding positions of Vice President (1996–1998), President (1998–2000). Dr Yeoh also held the position of National President of Alzheimer’s Australia from 2000–2005. Dr Yeoh is a professional member of the Guardianship Tribunal and was the NSW Delegate to Alzheimer’s Australia, from 1995–2000.
Andrew Watt
Andrew Watt’s father was diagnosed with younger onset Alzheimer’s disease in 2002. Since then, Andrew has worked closely with both Alzheimer’s Australia WA and Vic to raise awareness within both the Western Australian and Victorian communities. In 2007, Andrew was the opening speaker at the Alzheimer’s Australia’s National Conference in Perth where he shared his personal journey with Alzheimer’s disease. In 2009, Andrew was a steering committee member for the National Consumer Summit on Younger Onset Dementia. Andrew is currently undertaking a PhD within the University of Melbourne at the Bio21 Molecular Science and Biotechnology Institute where he is investigating blood-borne biomarkers of Alzheimer’s disease.

John Morrison
John Morrison is the Vice Chairman of Alzheimer’s Australia NSW. He has served on the Board for many years, and was Honorary Treasurer from 2003 - 2006. John has experience as a consultant and practitioner in finance, secretarial practice, corporate governance and risk management.

Dr Sean Maher
Dr Sean Maher is a Geriatrician and Head of the Department of Rehabilitation and Aged Care at Sir Charles Gairdner Hospital. Dr Maher graduated from the University of Western Australia and is a Fellow of the Royal Australasian College of Physicians. He was the Federal Secretary for the Australian and New Zealand Society for Geriatric Medicine (ANZSGM) from 2008 -2012 and has been a Federal Councillor of the society since 2005. Dr Maher has interests in delirium and dementia and coordinated the ANZSGM’s Position Paper on delirium, as well as assisting to develop the WA Department of Health’s Model of Care for Delirium and the Older Person. He is a senior lecturer in Geriatric Medicine at Edith Cowan University, Honorary Research Fellow at Curtin University and is Medical Director on the Board of Alzheimer’s Australia WA.

David Nathan (From April 2012)
David Nathan has endured the world of Alzheimer’s with his father succumbing in early 2012 after a ten year battle with the disease. Since 2006, David has been CEO of Australia’s largest indemnity insurer, Avant which has over 57,000 members and insures over 55 per cent of Australia’s medics. David has had considerable governance experience including Non-Governmental Organisation board membership. David has enjoyed an extensive career spanning law, commerce and economics.
SCIENTIFIC AND MEDICAL PANEL

Australia has some of the world’s leading dementia researchers and the Foundation is extremely privileged to be able to draw on their expertise and support. These research leaders advise the Foundation through membership of the Scientific and Medical Panel, support with research advocacy and policy activities and assist with rigorous external assessments of each funding application. Their expert guidance means that we fund only the best new and early career dementia researchers and high quality research projects.

Current members of the Scientific and Medical Panel are listed below. The many experts who have assisted the Dementia Grants Program by providing reviews, advice and external assessments are listed on page 39.

Professor Kaarin Anstey  
Chair, Scientific and Medical Panel  
Director, Centre for Research on Ageing, Health and Wellbeing  
Australian National University

Professor Lynn Chenoweth  
Professor of Aged and Extended Care Nursing  
University of Technology, Sydney  
Director, Health and Ageing Research Unit  
South Eastern Sydney-Illawarra Area Health Service, NSW

Professor James Vickers  
Chair of Pathology  
Head, School of Medicine, University of Tasmania

Professor Ralph Martins  
Director of Centre of Excellence for Alzheimer’s Disease Research and Care  
Foundation Chair of Ageing and Alzheimer’s disease  
Edith Cowan University

Professor David Ames  
University of Melbourne Professor of Ageing and Health  
Director, National Ageing Research Institute  
Royal Melbourne Hospital

Associate Professor Velandai K Srikanth (From January 2012)  
Associate Professor in the Department of Medicine, Monash University, Head of the Stroke and Ageing Research Group, Southern Clinical School, Monash Medical Centre (MMC)

Professor Wendy Moyle (From January 2012)  
Director of the Research Centre for Clinical and Community Practice Innovation (RCCPI)  
Griffith University

Associate Professor Peter Dodd  
School of Chemistry and Molecular Biosciences  
University of Queensland

Associate Professor Peter Dodd  
School of Chemistry and Molecular Biosciences  
University of Queensland
The Alzheimer’s Australia Dementia Research Foundation has existed as a research funding body under different names for almost 25 years, and I have been involved as Chair for all of that time.

The mission of the Foundation is to promote, disseminate and fund Australian research into dementia. It does this primarily through a competitive program of research grants, scholarships and fellowships, with a focus on building capacity by supporting doctoral and post-doctoral researchers and early career researchers.

Over the past 12 years, the Foundation has distributed over 120 research grants, travel grants, scholarships and fellowships through the Dementia Grants Program, with a total value close to $5 million. For the first time in 2011, the total value of awards offered by the Foundation exceeded $1 million – up from just $110,000 only six years before. It has increased to $1.7 million in 2012 and is on track to exceed $2 million in 2013.

This growth in the value of the program and the support we can offer to early career researchers has only been possible with the increased support from members of the public, private and charitable organisations, and members of the Alzheimer’s Australia Federation.

If the trend increases, the Foundation should achieve its long-standing objective of providing $3-5 million for dementia research funding per year; on par with the research investment of other leading health charities, and around 10-15 per cent of the total investment in dementia research by the Federal Government, through the NHMRC.

While the research dollars provided through the Foundation are still relatively small in the context of the total investment in dementia research, the Foundation does play a very important role in supporting students and early career researchers, and helping them to establish a foothold as independent dementia researchers. With your continued support we can offer more funding to dedicated researchers, assisting them in working towards a World Without Dementia.

I would like to thank the Board of Directors for their wise advice, and Glenn Rees for his continuing inspired leadership of Alzheimer’s Australia. I am very happy to welcome Mr David Nathan to the Foundation’s Board of Directors and would like to acknowledge Katherine Bowditch and Angela McKeegan for their hard work managing the business of the Foundation throughout 2011-12. I look forward to a productive 2013 in which we are able to fund even better and more research, build research capacity and work towards preventing, curing and better care for all forms of dementia.

Professor Henry Brodaty AO,
Chairman
Over the past 25 years, researchers have made many important discoveries which mean we now have a much better understanding of the diseases of the brain which lead to dementia.

However, we have not yet developed a way to stop the progression of dementia or to eliminate the diseases that cause the condition.

Given the projected increase in the numbers of people with dementia – over three million Australians between 2012 and 2050 – we need to get serious about the research effort required. Australia is home to some of the leading dementia researchers in the world, and we have been at the cutting edge of international research, in many areas, for decades.

However, public funding for dementia research has not kept pace with funding for other chronic diseases. The dollars going to cancer, diabetes, heart disease and mental health have increased substantially over the past decade, while funding for dementia research by comparison has practically stood still. As a result, dementia research is failing to attract the best and brightest new researchers, and is losing talented scientists to other fields.

This is where the Alzheimer’s Australia Dementia Research Foundation is able to make its greatest contribution. We supported close to 20 students and early career researchers with funding over $1 million in 2011-12 in the hope that they will go on to develop independent research careers and compete for vital research funding along with scientists in other disciplines. In doing so, they will be following in the footsteps of many of the Foundation’s grant recipients before them.

Research into new treatments for dementia suffered a number of setbacks during 2011-12, with several international drug trials failing to demonstrate beneficial effects, and major pharmaceutical companies rethinking their investments in drug development for dementia. However, we remain optimistic that ways will be found to delay the progression of dementia so that we achieve a dementia free life for more Australians.

What are the reasons for optimism?

In the past 10 years we have developed a much better understanding of the modifiable factors which can increase the risk of dementia. We now know that the same actions that are good for your heart also reduce your risk of dementia. We also know that if we develop interventions to delay the onset of dementia, we have the potential to significantly reduce the number of people living with dementia.

Multiple strategies are being pursued to delay or reduce the risk of dementia, including therapies to neutralise the toxic effects of proteins in the brain, vaccination, stem cell therapies and gene therapy. New medications are in trials to slow or delay the progress of dementia in the brain. New medical technologies are being developed to detect dementia years before symptoms emerge so that it is possible to treat those most at risk and we are now beginning to understand the environmental, behavioural and genetic risk factors to help people reduce their risk of developing dementia.

Achieving a World Without Dementia is no different from the visions adopted for other major chronic diseases, for example diabetes, cancer, heart disease or AIDS. We are often not able to cure these conditions, but we are increasingly able to treat and manage them to give Australians a better quality of life.

I would like to express our gratitude to the Board, to the Scientific and Medical Panel, and to the dementia researchers who have assisted with grant assessment and administration during the year. I would also like to acknowledge some of the large donations received during the year from the Hiley-Allars family, the Trengove family, the Silvia and Charles Viertel Foundation, Resthaven Inc, the Commonwealth Bank and the Rosemary Foundation.

Finally, I would like to thank Ita Buttrose, AO OBE, National President of Alzheimer’s Australia for her invaluable support of the Foundation throughout 2011-12.

Glenn Rees,
Company Secretary
A YEAR IN REVIEW: FUNDRAISING

Alzheimer’s Australia Dementia Research Foundation is dedicated to funding the brightest new Australian dementia researchers in their fight against dementia. However, we can only do this with the support of the thousands of people around Australia, and in some cases, around the world, who feel passionately enough about the importance of dementia research to donate or fundraise to support the work of the Foundation.

We’d like to say thank you to everyone who has donated or raised money for us during 2011-12 and to showcase some of the inspirational efforts of our supporters.

Chris Turner
Sea to Sentinel Expedition

Chris Turner is an avid hiker and mountaineer who set out to walk from the Chilean coast to the summit of Aconcagua, the highest mountain in South America, and the highest peak outside of Asia at a height of 6,962m.

“When I was planning this expedition I always felt that I should use it as an opportunity to raise funds for a worthwhile cause. Alzheimer’s disease has been an ever present part of my life for the last five years. My mother-in-law who had Alzheimer’s disease passed away in June, 2011 and several close relatives and parents of friends have recently been diagnosed. I approached Alzheimer’s Australia to see about undertaking a campaign. They were very supportive and within a few weeks we had a website and a donation method set up.”

On the expedition itself, Chris says that mountain climbing offers a unique way to appreciate the value of setting and achieving goals:

“Everything leading to the summit is a series of goals, often starting months if not years prior to that moment. Many of the intermediate waypoints would seem insignificant without the lure of the ultimate purpose. Some become trials of what seems like equal magnitude to the final goal. Yet at every step, the thought of taking that last pace, of being where you have visualized for so long drives you, makes the hardships, the disappointments, the sacrifices all worthwhile.”

Through the generosity and support of family and friends, Chris raised thousands of dollars which will help fund vital dementia research.

Top: Starting his journey on the Chilean Pacific coast at Con Con
Above: Approaching Base Camp at 4,200 meters
Since 2009, Libby Day has been organising an annual fundraising event to celebrate her mother, Molly, and Molly’s love of music. Her main goal is to raise awareness and funds for dementia research.

“I worked as a community nurse for years and had often heard dementia being referred to as the ‘long, slow goodbye.’ I didn’t realise just how long and hard it would be until my mum developed dementia.

We call the events ‘Molly’s Song’ because it is a positive, happy name. Apart from celebrating the important role music has played in my Mum’s life it also reflects the changes to her world since being diagnosed with Alzheimer’s. As her condition has progressed her ability to participate in music activities has decreased.

Each event has been such a success. It is wonderful to be able to do something positive at what is otherwise a very sad time for my family.

The first event was held in a small restaurant in Noosa to raise funds for dementia research. We had 45 people attend on the night, with quite a few names on a waiting list. The local paper reported on the event. After the success of the first fundraising activity we decided we could hold an annual Molly’s Song event. We had a logo and banner designed. The following year we held Molly’s Song at a local golf club with an Italian Banquet, raffles, live music and dancing for 120 people. We’ve also had a Jazz night. As well as raising awareness and funds for research we want people to enjoy themselves and keep singing and dancing because dementia robs people of that. The local community are very, very supportive – there are so many other fundraising events going in this area but the local businesses have been keen to donate prizes and support us in any way they can. Many have had their own personal experience of the effect of dementia on a loved one or friend.

The people who keep coming back to the Molly’s Song events and helping each year are my Dementia Champions. These events are about everyone’s mum, dad, wife, husband, sister, brother or friend – not just my mum. We need to do whatever we can so that they can all keep singing and dancing.”
Alzheimer's Australia Dementia Research Foundation Annual Report 2011–12

Trengove Family
The Lost Memories Charity Dinner

In 2006, Rhonda Trengove was diagnosed with Posterior Cortical Atrophy (PCA) a rare form of dementia. Her husband Graham tells her story.

"Until 2002, Rhonda was a happily married hard working mother of four children aged 15 to 23. For Rhonda, life was just beginning. We were both looking forward to an easier lifestyle of less work, grandchildren and travel. In mid-2002 however, Rhonda left her job as a pharmacy assistant after struggling with her work commitments for the previous 12 months. The problems she’d been experiencing were unusual as Rhonda had worked in the pharmacy industry since leaving school and was very capable and efficient in her job.

In the 12 months that followed, Rhonda (in the early stages of dementia, unbeknownst) amazingly completed her Certificate III in community services for aged care however she continued to encounter problems with work – she was coming home completely exhausted and mentally drained.

After many months of visiting a number of neurologists, repeated scans and tests, we finally had a diagnosis: dementia. Rhonda was referred to the Cognitive Disorders Clinic at Concord Hospital on the 15th of May 2006 where she was formally diagnosed with PCA.

Rhonda gradually became very isolated and began to suffer from depression, anxiety and the gamut of emotions; anger, frustration, sadness, fear and loneliness at the affect this illness was having on her. Rhonda had always been a people person, but the illness had begun to forcibly take that away from her.

With the help of Carewest and other organisations, we were able to keep Rhonda at home until early 2011, before having to make the difficult decision to find her a place in permanent care. She is now living in the dementia wing at Wontama nursing home in Orange, and receives assistance with all aspects of daily activities and functions.

Rhonda’s condition has progressed rapidly since going into care and she is now in the very advanced stages of dementia. I feel dementia was particularly hard for Rhonda in the early stages. Not only was she unusually young, but the kind of dementia that
Rhonda has meant that for a very long time she maintained her awareness of what was happening.

Our family wanted to do something to raise awareness and help other people in our situation, both now and in the future, and we discussed lots of options. Eventually, we decided on a dinner dance and charity auction and after many months of talk and not much action it was Todd who finally contacted Alzheimer’s Australia to get things moving.

We’d planned on 200 people but as word got around, all 416 tickets sold out. Local businesses and council pitched in with sponsorship and prizes, local identities James Grant and Reg Kidd agreed to host the night, and Sue Pieters-Hawke and her daughter Sophie came as special guests.

There was a great vibe on the night itself, with good food and music and a reasonable amount of beverages flowing. People put their hands in their pockets (the winning bid for a framed Manly NRL jersey was $3,000) and the event raised $55,000 in total. I think this was so successful because so many people and their families have been touched by dementia in some way and they all welcomed the opportunity to do something positive.

Staging this event was a huge amount of work, but it was amazingly gratifying and uplifting for us as a family to see such a response and to raise so much for dementia research. We extend our thanks to all involved and our community at large, and we hope to stage more fundraising events in the future.”

The Hiley-Allars Family
Fund to support dementia research

In 2011, the Hiley-Allars family set up a fund to support research into dementia that has had a major impact on their lives. In 2012, the Hiley-Allars Award, valued at $50,000 was advertised as part of the Foundation’s Dementia Grants Program. Another Hiley-Allars Award will be offered in 2013. The Foundation would like to thank the family, and in particular Ron Allars for his ongoing support and commitment to dementia research.

Left: Professor Henry Brodaty with the Hon Tony Abbott and Mr Ron Allars, Director of the Rotary Club of Brookvale at the Club’s 30th birthday luncheon. At the event, the Rotary Club of Brookvale presented Professor Brodaty with a cheque for $25,000 to support dementia research through the Hiley-Allars fund.
A YEAR IN REVIEW:
CONSUMER DEMENTIA RESEARCH NETWORK

The Alzheimer’s Australia Consumer Dementia Research Network (CDRN) consists of 25 people from across Australia who either have dementia or who care for a person with dementia. CDRN members are involved with a range of dementia research and implementation activities across Australia.

In 2012 members of the CDRN worked with the Alzheimer’s Australia Dementia Research Foundation to revise grant application forms to include sections on ‘consumer involvement in research’ and ‘knowledge dissemination.’ They also nominated younger onset dementia as a priority research area in which the Foundation would offer a specific award. The Foundation would like to thank the CDRN for their assistance throughout 2011-12.
## 2011 DEMENTIA GRANTS PROGRAM

### SUMMARY

<table>
<thead>
<tr>
<th>Award Type</th>
<th>Award Amount</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alzheimer’s Australia Dementia Research Foundation Project Grants (x5)</td>
<td>$30,000</td>
<td>$150,000</td>
</tr>
<tr>
<td>The Hazel Hawke Research Grants in Dementia Care (x2)</td>
<td>$30,000</td>
<td>$60,000</td>
</tr>
<tr>
<td>Alzheimer’s Australia Dementia Research Foundation Part Fellowships (x3)</td>
<td>$45,000 Per Annum for 2 years</td>
<td>$270,000</td>
</tr>
<tr>
<td>Viertel Part Fellowship</td>
<td>$45,000 Per Annum for 2 years</td>
<td>$90,000</td>
</tr>
<tr>
<td>Rosemary Foundation Travel Grant</td>
<td>$15,000</td>
<td>$15,000</td>
</tr>
<tr>
<td>Alzheimer’s Australia Dementia Research Foundation PhD Scholarships (x3)</td>
<td>$30,000 Per Annum for 3 years</td>
<td>$270,000</td>
</tr>
<tr>
<td>Viertel PhD Scholarship</td>
<td>$30,000 Per Annum for 3 years</td>
<td>$90,000</td>
</tr>
<tr>
<td>Resthaven Inc PhD Scholarship Quality in Dementia Care</td>
<td>$30,000 Per Annum for 3 years</td>
<td>$90,000</td>
</tr>
<tr>
<td>Total value of program</td>
<td></td>
<td>$1,035,000.00</td>
</tr>
</tbody>
</table>
Background
The Hazel Hawke Alzheimer’s Research and Care Fund was established in 2004 at the expressed wish of Hazel Hawke, who chose to make public the fact that she is living with Alzheimer’s disease, in late 2003. In 2004, Hazel’s daughter Sue Pieters-Hawke co-authored a book with Hazel Flynn called Hazel’s Journey: A personal experience of Alzheimer’s. Money from each copy sold goes to the Hazel Hawke Alzheimer’s Research and Care Fund. This fund is also open for public donations.

Hazel Hawke Research Grants in Dementia Care
In 2011, funds raised by the Hazel Hawke Research and Care Fund were put towards funding two projects with a total value of $50,000. The Foundation is very grateful for the ongoing support of both Sue Pieters-Hawke and Sophie Pieters-Hawke, Hazel’s granddaughter, who has been involved in fundraising activities through the Forget-Me-Not Girls.

In 2012, the Hazel Hawke Research and Care fund offered a $50,000 award for dementia research.
DR AMEE Baird
University Of Newcastle

Music as a memory aid in Alzheimer’s Disease.

“My project will investigate the use of song as a memory aid in Alzheimer’s disease (AD). There is accumulating evidence that music can enhance memory in patients with various neurological conditions, including dementia. This study will compare learning and recall of verbal information (what day and time a particular task was done) in a music context (as lyrics to a familiar song) with recall of this information in the spoken form.

It will be the first study to examine the effect of musical background on recall of information in a music context by comparing musicians and non-musicians (healthy elderly and individuals with AD). Impaired memory is the main symptom of AD, and there is an urgent need to develop effective memory aids for this population. The findings have the potential to improve the quality of life for individuals with AD and their carers, and to provide an important scientific contribution to our understanding of memory.”

DR JEAN Tinney
National Ageing Research Institute

Interpreter Mediated cognitive assessments – stakeholder experiences informing guidelines and training DVD

“In this project we are exploring clinician, family member and interpreter perceptions of their experiences of a multicultural cognitive assessment involving the use of an interpreter. A second aim is to develop interpreter guidelines and a training DVD for the conduct of cognitive assessments. Anticipated findings will highlight the challenges for all stakeholders in the multicultural cognitive interview, contributing to greater understanding between all parties. The new guidelines and training materials will educate and support clinicians as well as interpreters, enabling improved collaboration between these groups of professionals. This will improve the experience for patients and their families, and contribute to better diagnosis and care planning.

“My background is in communication and language teaching, cross-cultural education and training. There were several important triggers for my current involvement in research into ageing, dementia and dementia care. These include; a nursing home communication study, my mother’s entry into residential aged care and my ethnographic PhD study exploring the role of communication in sustaining aged care residents’ sense of self and wellbeing. As a volunteer four days a week for eight months, I had close contact with people with dementia and their families and the many dedicated staff who strive to meet the needs of both groups. My primary research activity now includes older age mental health, research with culturally and linguistically diverse groups, and aged care service provision in hospitals, residential and community care.”
The Foundation’s Dementia Research Grants are intended to help new dementia researchers on the beginning of their journey towards independent research careers. The awards support researchers working in all areas of dementia research, from the lab to the community.
DR. MUIREANN IRISH
Neuroscience Research Australia

The future looks bright – Episodic Future thinking as a diagnostic aid in frontotemporal dementia and Alzheimer’s disease.

“The ability to remember events from the past represents one of the most fascinating and complex processes of the human brain. It is only when memory for the past begins to fail, however, that we appreciate how complex this process truly is. Recent research has revealed an exciting link between the ability to remember the past and the capacity to imagine and to envisage possible events in the future. My latest line of research is concerned with the link between memory for the past and imagining the future in individuals with dementia. In my research, I investigate the capacity for ‘future thinking’ in early onset dementia, specifically frontotemporal dementia and Alzheimer’s disease. I used structural MRI scans of the brain to determine which regions are crucial for the ability to remember past events and to imagine possible future events. I am also interested in how the ability to imagine the future might be related to other cognitive and behavioural changes typically seen in dementia. For example, on an everyday level, if an individual with dementia is unable to imagine their future, does this result in a loss of motivation or apathy for upcoming events? By studying the capacity for future thinking in dementia, and its neural underpinnings, I hope to shed light on some of the mechanisms underlying the cognitive and behavioural disturbances characteristic of these disorders.”

DR. ZOE TERPENING
University of Sydney

Investigating napping and memory with people at risk of dementia

“While 59% of patients with mild cognitive impairment (people at increased risk of dementia) report sleep disturbances, there are very few interventions targeting sleep in older adults at risk of dementia. In my current project we plan to evaluate whether controlled, planned napping is an effective method for improving memory and cognition and whether this relates to specific neurophysiological markers in sleep. It is expected that napping will be superior to the waking state for memory consolidation, and will be most beneficial in people with specific sleep profiles (greater sleep spindle density and delta power during slow wave sleep).”
Alzheimer’s disease, Cognition and Cerebrospinal Fluid: are they associated?

“Cognitive changes after surgery occur in the elderly, yet the cause remains unknown. We plan to study cognition in patients having hip surgery in which general and spinal anaesthesia are used together. This allows us to sample spinal fluid which will be analysed for substances which identify a predisposition to Alzheimer’s disease. By comparing the results to a group of subjects who have not undergone surgery, we hope to identify if anaesthesia and surgery exacerbate this predisposition. Recent research revealing the ability to detect Alzheimer’s disease in the cerebrospinal fluid (CSF), presents an opportunity to explore the effect of anaesthesia and surgery on cognitive outcomes and the relationship to Alzheimer’s pathology. We plan to track Post Operative Cognitive Dysfunction (POCD), cognition, function and dementia after anaesthesia and surgery in a pilot group of patients using CSF analysis to relate POCD to Mild Cognitive Impairment and dementia. If anaesthesia and surgery accelerate the onset of these changes in patients with the CSF signature of Alzheimer’s disease, this will provide evidence for a large definitive study to be undertaken.

I am inspired by people and their families who open their homes and their hearts to our team. We conduct lengthy neuropsychological assessments over many years, and request the completion of long questionnaires, and our team of research assistants are continually welcomed into people’s homes and their lives, almost always with a cup of tea!”

St. Vincent’s Hospital, Melbourne

LISBETH EVERED

La Trobe University

Stress and health in spouses of people with early-stage Alzheimer’s disease: the effects of a memory training intervention

“Caring for a family member with dementia can be a highly rewarding experience; however it can also have deleterious effects on a carer’s psychological and physical health. Alarmingly, carers of people with dementia are reported to have higher rates of morbidity and mortality relative to non-carers, with carers at increased risk of depression, cardiovascular illness, and impaired immune response.

This study will investigate the relationship between perceived stress and psychological and physical health of carers of people with early stage dementia. The study will also investigate the effect of a multicomponent intervention (psychoeducation and memory strategy training) delivered to both carer and care recipient on carer health outcomes”.

LINDA MCAULIFFE

La Trobe University
Alzheimer’s Disease is a progressive and eventually fatal brain disease. Expression of a gene called TrkB is critically important for neuron survival, normal brain development and higher brain functions. I have recently found that the beneficial effects of TrkB is reduced in the brains of patients with Alzheimer’s disease by increased expression of non-functional TrkB variants. This research project will determine how expression and function of TrkB is compromised in Alzheimer’s disease by identifying the cellular processes that are responsible for its reduction. In particular, I will focus on how non-functional variants of TrkB are increased. Understanding the cause of Alzheimer’s disease will help define better treatments. My research is important because it will help shed light on how neurons are impacted in the disease process.

The outcomes of my research are highly important as it will identify how a gene critical for neuron survival and brain function is decreased in Alzheimer’s disease. My research could potentially implicate a candidate gene expression marker of Alzheimer’s disease that may surface prior to the onset of cognitive decline.

Understanding the cause of Alzheimer’s disease will help define better treatments by providing novel avenues for therapeutic targeting to enhance neuron survival and function (e.g. increasing TrkB expression and function) in people with Alzheimer’s disease.
Alzheimer’s Australia Dementia Research Foundation - Victoria was established to distribute funds generously donated to Alzheimer’s Australia Victoria for research.

The funds are managed and administered by Alzheimer’s Australia Dementia Research Foundation on behalf of Alzheimer’s Australia Victoria, and are offered alongside the Annual Dementia Grants Program. Grants are awarded annually by the Victorian Foundation’s Board, chaired by Associate Professor Michael Woodward, Director of Aged Care Services at Austin Health.

The grant applications are subject to a rigorous external assessment process and are further considered by the Alzheimer’s Australia Dementia Research Foundation’s Scientific and Medical Panel.

The funds are used to provide research grants to dementia researchers, with priority given to projects based in Victoria or with potential benefits especially relevant to Victorians living with dementia.
Alzheimer’s Australia Dementia Research Foundation  Annual Report 2011–12

PROFESSOR CAROLYN UNSWORTH
La Trobe University

A randomised controlled trial to determine the effect of location of assessment and number of assessments on driving test performance of people with recently diagnosed dementia.

“I am a Professor of Occupational Therapy at La Trobe University. My main research interest is driver assessment, rehabilitation and community mobility. I recently published a research-based book called the OT-DORA Battery for driver assessors to determine fitness-to-drive of older and/or functionally impaired drivers. As an occupational therapist, I am passionate about assisting people to be independent in the occupations (activities) they want to or need to do.

Our research team includes three occupational therapists who are driver assessors as well as a specialist physician in geriatric medicine and the care of people with dementia.

It is vital that drivers in the early stages of dementia who are able to continue to drive are supported to maintain this independence. Many people who have a new diagnosis of dementia are referred for an occupational therapy (OT) driver assessment. Since driving is an over-learned skill, it may be possible for some individuals with dementia to continue to drive safely for some time following diagnosis and undergo periodic re-assessment to ensure fitness-to-drive. Drivers are often nervous when undergoing an assessment, and may perform better on a subsequent test. Additionally, while some drivers may perform poorly on the standard, unfamiliar test route, performance may improve when tested in their local area leading to a recommendation for local-area-only licence. Our research will determine the effect of location and number of assessments on driving performance of people with dementia.

This research will provide evidence to support the development of an optimal driver assessment protocol for people in the early stages of dementia. The research will determine if this protocol includes a preliminary drive prior to actual testing, and whether only local area testing should be recommended to individuals.”

PROFESSOR RAJIV KHOSLA
La Trobe University

Affective Communication Robots for supporting care givers and elderly with dementia in Home-based Care.

“Assistive technologies can play a useful role in improving quality of care and encouraging independent living and ageing in-place. The purpose of this project is to determine the effectiveness of affective communication robots to support care givers and elderly with dementia in Victoria.

The effectiveness will be measured in terms of utility of the robot to the care giver and impact on well being of the elderly as result of their interactions. The project has been prompted by first ever successful field trials of affective communication robot (Matilda) in Regional Northern Queensland and Victoria in 2010 and 2011 respectively. Dementia specific applications and services will be designed in Matilda. Research strategy will involve three-stages to test the benefits of Matilda supported services facilitating engagement, personalisation of care and social participation, usefulness and healthy living.”

2011 VICTORIA GRANT RECIPIENTS
POSTDOCTORAL FELLOWSHIP AWARDS

Each year, the Foundation awards a number of two year, post-doctoral fellowships to some of the most talented emerging dementia researchers in Australia. These fellowships support the researchers’ salaries – in full, or in partnership with their University or research institute, and are a vital stepping stone in the path to an independent research career.
THE VIERTEL FOUNDATION POSTDOCTORAL FELLOWSHIP

DR NADY BRADY

University of New South Wales

Understanding Oxidative Stress in the Brain to prevent Neurodegenerative Diseases.

"Dementia is one of the top 5 causes of death in Australia with an increasing incidence due to an aging population. Significant evidence points to oxidative stress (OS) as a major underlying factor in brain cell degeneration. Unfortunately, it is not known at what stage of life this OS begins in humans or what behaviours influence OS in the human brain. As OS underlies brain cell degeneration and the development of dementia, answers to these questions will contribute to the development of strategies that will help maintain brain cell function into older age.

To shed light on these questions we will use serum samples collected across a wide age range enabling us to investigate: at what age OS levels begin to increase in human cerebrospinal fluid and whether diet, lifestyle and/or psychosocial factors are associated with OS levels in human serum.

We predict that oxidative stress in the brain will increase with at least one or more risk factors including, poor diet and lifestyle choices and psychosocial stress. Some level of OS will be observable at all stages of life, but most markedly after middle age.

It is a great pleasure to have been the sole recipient of the Viertel Foundation Postdoctoral Research Fellowship. I am deeply grateful to the Alzheimer’s Australia Dementia Research Foundation and the Viertel Foundation for sponsoring my research."

THE ALZHEIMER’S AUSTRALIA DEMENTIA RESEARCH FOUNDATION POSTDOCTORAL FELLOWSHIP

DR JEFFREY LIDDELL

University of Melbourne

Investigating the cellular targets of therapeutic metal complexes for the treatment of Alzheimer’s disease

“Neurodegenerative diseases such as Alzheimer’s disease still lack effective treatments. Our research is pursuing a new therapeutic strategy using a class of copper-complex compounds which we have demonstrated to have strong potential for the treatment of multiple diseases including Alzheimer’s disease, Parkinson’s disease and Amyotrophic Lateral Sclerosis. As these compounds have such wide-ranging effectiveness, it suggests the compounds are regulating targets common to all these conditions. My research focuses on delineating the specific molecular and biochemical pathways that contribute most to the therapeutic activity of these compounds. This is critical for the further development of the compounds to maximise their efficacy and specificity, and may help to understand the causes underlying these diseases.

As a neuroscientist, I feel privileged to be working towards more effective therapeutic treatments and a better understanding of the causes of diseases such as Alzheimer’s disease. While I am driven to make discoveries and learn new things, it is especially gratifying that these discoveries could make a real impact to the lives of those living with dementia and their families."
POSTGRADUATE SCHOLARSHIP AWARDS

Each year, the Alzheimer’s Australia Dementia Research Foundation calls for applications from newly graduated students who are interested in undertaking postgraduate training in dementia research. Applications are highly competitive, and those who are awarded a three-year postgraduate scholarship to undertake a PhD in dementia research by the Foundation are among the top research students in Australia.
CHRIS MORAN

Monash University

Brain Ageing in Type 2 Diabetes Mellitus (DM).

“I am studying the relationship between Type 2 Diabetes Mellitus (T2DM) and Alzheimer’s disease. T2DM is associated with an increased risk of developing Alzheimer’s disease and my research aims to understand the mechanisms underlying this association. As the incidence of Alzheimer’s disease and T2DM increase in our society, understanding their link becomes important. I am comparing brain MRI scans, cognitive tests and blood tests between people with and without T2DM. In addition I am using Positron Emission Tomography (PET) brain scans to study how T2DM affects brain metabolism. Both of these studies will assist in clarifying how T2DM promotes the risk of AD and will guide the prevention and treatment of the disease.

I am based at the Stroke and Ageing Research Group, Monash Medical Centre and I completed my training as a Geriatrician this year. During my training, I observed the health, social and carer burden associated with Alzheimer’s disease in the hospital, out-patient and community settings. This experience has made me keen to add to research in this area, and hopefully make a difference to people with Alzheimer’s disease and those with T2DM.”

MYLES MINTER

The University of Melbourne

Controlling Neuro-inflammation in Alzheimer’s Disease.

“Alzheimer’s disease is a common neurodegenerative disorder, with 280,000 Australians currently diagnosed with the disease. Due to an aging population, this is expected to increase to nearly a million people by 2050. Alzheimer’s disease accounts for greater than 60% of all cases of dementia and is a disease with huge socio-economic implications. Current therapeutic treatments have been ineffective in combating the disease progression. My research addresses an aspect of Alzheimer’s disease pathology that has not been previously targeted therapeutically: neuro-inflammation. More specifically, this study will focus on a key regulator of neuro-inflammation, the type-1 interferons, and will investigate their contribution to disease pathogenesis. This research will potentially identify a novel therapeutic target for more effective treatment.”
YOONKYUNG (RACHEL) CHANG

The University of Queensland

Synaptic Proteome in Alzheimer’s Disease.

”Synaptic dysfunction occurs early in Alzheimer’s disease (AD) and is recognized as a primary pathologic target for AD treatment. Synapse degeneration or dysfunction contributes to clinical signs of dementia through altered neuronal communication and the degree of synaptic loss strongly correlates with cognitive impairment. Through this study, synaptic proteins that are differentially expressed in the diseased state will be identified. Studying AD at a protein level will help unravel the molecular mechanisms underlying AD pathogenesis. This will aid the timely diagnosis of AD, help monitor disease progression and identify therapeutic targets that might slow AD progression.

I have the privilege of working with human autopsy brain tissues at our lab which is part of the Queensland Brain Bank. I believe this research is extremely important because the number of people who will develop Alzheimer’s disease is expected to rise, and with it the costs to our society.”

VIERTEL FOUNDATION POSTGRADUATE SCHOLARSHIP IN DEMENTIA

CHARLES MALPAS

The University of Melbourne


“The primary aim of my research is to evaluate the effectiveness of a novel drug for the treatment of Alzheimer’s disease. The drug in question, sodium selenate, works by clearing one of the major pathological hallmarks of the disease from the brain, and has been successful in several animal studies. This study is the first attempt to use the drug in humans with Alzheimer’s disease, and is currently being tested in a cohort of patients Melbourne. As part of the study, participants will undergo brain scans at the start and end of the trial. My project involves analysing these brain scans at the Melbourne Brain Centre to see if the drug has resulted in improvements in brain structure and function.

I have long had an interest in Alzheimer’s disease research, and my involvement in this project gives me the opportunity to contribute to finding a viable treatment. Eventually, I hope that drugs such as ours will provide much needed relief and hope to people with dementia and their families. Perhaps my biggest motivation comes from my interactions with people with dementia as part of my training in clinical neuropsychology. Although the science of Alzheimer’s disease is fascinating, and a motivation in itself, I find the human element to be the most compelling. To be able to make just a small contribution to improving outcomes for these people is incredibly rewarding, and I am exceptionally grateful to Alzheimer’s Australia for their ongoing support.”
Resthaven Incorporated was established in 1935 as a not-for-profit, aged care community service of the Uniting Church. Resthaven Inc. delivers high quality, fully accredited, responsive care services for older South Australians and their carers. Resthaven Inc. has partnered with Alzheimer’s Australia Dementia Research Foundation In 2011, we offered the Resthaven Inc. 75th Anniversary Postgraduate Research Scholarship, to a student undertaking a research PhD in an area relevant to quality in dementia care. In 2012, Resthaven Inc. have offered a $150,000.00 award through the Foundation, for research specifically into Dementia and Pain.
Background
Resthaven Inc. offers a range of in-home community care and support options throughout metropolitan Adelaide, the Adelaide Hills, Murraylands, Riverland and across the Limestone Coast, with around 8,000 clients benefiting from these services. Residential aged care is offered to more than 1,000 older people at ten locations. Resthaven employs approximately 1,700 staff, who are supported by 450 volunteers.

Many of the people to whom Resthaven Inc. provides services live with dementia, or are carers of people living with dementia. Resthaven Inc. not only provides high quality aged care services and support, but also invests significantly in research and projects related to dementia. This research includes diagnosis, early intervention, raising community awareness, supporting carers, and palliative care.

RESTHAVEN INC. 75TH ANNIVERSARY POSTGRADUATE SCHOLARSHIP 2011 WINNER
SCOTT CROUCH
La Trobe University

Network of Emotionally Intelligent Communication Robots for Ageing-In-Place.

“This project aims to develop and use a network of emotionally intelligent communication robots to support the daily activities of elderly persons with mild dementia. The network of communication robots is aimed at helping overcome the cognitive impairments present in dementia by providing a communication channel between the person and a close relative/carer, reminding about their medication and daily schedule, reporting back to the relative/carer, and improving their social well-being by engaging in conversations and various activities. In particular, we are interested in how the robots can help people overcome cognitive deficits related to dementia and improve their social well-being. The wider implications of this are that elderly persons with dementia will be able to live in their own homes for longer, more comfortably and with greater independence, improving their quality of life. This is part of an emerging aged care paradigm known as ‘ageing in place’, the ability to live in one’s own home with relative independence and comfort for as long as possible. This research is based on existing research involving communication robots and elderly residents in nursing homes.

Every person with dementia is different and we must take into account their individual needs and difficulties when working with them. Robotics in aged care is an emerging area of research and there is only a small amount of existing literature so the level of interest shown from people, particularly those working in aged care, to participate in this kind of work has been great.
ROSEMARY FOUNDATION
TRAVEL AWARDS

The Rosemary Foundation is a charity capital fund that works to perpetuity to help those people with Alzheimer’s disease, other dementias and memory loss as well as giving much needed support to their families, friends and carers. The Rosemary Foundation supports research and each year funds a Travel Award for a researcher to meet and work with leading experts in other countries. These researchers learn new skills and expertise and bring this knowledge to Australia.
DR DANIJELA GNJIDIC

University Of Sydney

Drug Burden Index and association with adverse outcomes in community-dwelling people with Alzheimer’s Disease.

"I am a NHMRC Early Career Fellow at the Faculty of Pharmacy, University of Sydney. I was awarded a PhD and Masters of Public Health in 2010 by the Sydney Medical School, University of Sydney. Following my doctoral training, I conducted post-doctoral training at the University of Eastern Finland. My research focuses on clinical pharmacology, pharmacoepidemiology, clinical studies of older people and analysis of health register databases.

The objective of this project is to work alongside leading experts in Finland. I aim to describe the exposure to high risk medicines, measured using the Drug Burden Index, and to correlate the high risk medicines exposure with mortality and hospitalisation in older people with Alzheimer’s disease. This project will contribute to better understanding of risks associated with medicines in older people with Alzheimer’s disease. Identifying strategies to improve the quality use of medicines in older people with Alzheimer’s disease in Australia requires a reliable evidence base on the relationship of medication exposure with adverse health outcomes."

DR ADRIENNE WITHALL

The University of New South Wales

Improving Service Provision for Australian Clients with Younger Onset Dementia and Alcohol Related Dementia – Translating knowledge from the Netherlands and Scotland.

“My focus is on younger people with dementia and their carers; determining their prevalence, symptoms, and service needs, as well as the experiences of their carers and children.

Little is known about how best to provide services for those with younger onset dementia (onset of symptoms under the age of 65) and for those with dementia due to long-term alcohol abuse. These groups often fall through the gaps of existing dementia services. For those with alcohol related dementia there is an additional negative stigma that can prevent them from receiving much-needed care. The aim of this project is to gain expertise from international teams who are performing research and working with clients in the community and residential care so as to improve services for Australians with these diagnoses.”
## 2012 DEMENTIA GRANTS PROGRAM

<table>
<thead>
<tr>
<th>Award Type</th>
<th>Award Amount</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alzheimer’s Australia Dementia Research Foundation</td>
<td>$30,000 (x3)</td>
<td>$90,000</td>
</tr>
<tr>
<td>Project Grants (x5)</td>
<td>$50,000 (x3)</td>
<td>$150,000</td>
</tr>
<tr>
<td>The Rhonda Trengove Dementia Awareness Research Grant</td>
<td>$50,000</td>
<td>$50,000</td>
</tr>
<tr>
<td>The Hazel Hawke Research Grant in Dementia Care</td>
<td>$50,000</td>
<td>$50,000</td>
</tr>
<tr>
<td>The Hiley-Allars 2012 Award</td>
<td>$50,000</td>
<td>$50,000</td>
</tr>
<tr>
<td>The Commonwealth Bank Community Seeds Grant</td>
<td>$30,000</td>
<td>$30,000</td>
</tr>
<tr>
<td>Alzheimer’s Australia Dementia Research Foundation Victoria Grants (x2)*</td>
<td>$50,000*</td>
<td>$100,000*</td>
</tr>
<tr>
<td>Resthaven Inc Award for research into Dementia &amp; Pain</td>
<td>$150,000</td>
<td>$150,000</td>
</tr>
<tr>
<td>Alzheimer’s Australia Dementia Research Foundation Full Fellowship</td>
<td>$90,000 Per Annum for 2 years</td>
<td>$180,000</td>
</tr>
<tr>
<td>Alzheimer’s Australia Dementia Research Foundation Part Fellowship</td>
<td>$50,000 Per Annum for 2 years</td>
<td>$100,000</td>
</tr>
<tr>
<td>Viertel Part Fellowship</td>
<td>$45,000 Per Annum for 2 years</td>
<td>$90,000</td>
</tr>
<tr>
<td>Sachdev (NSW) Part Fellowship</td>
<td>$50,000 Per Annum for 2 years</td>
<td>$100,000</td>
</tr>
<tr>
<td>Epsilon Research Fund Postdoctoral Fellowship</td>
<td>$60,000 Per Annum for 2 years</td>
<td>$120,000</td>
</tr>
<tr>
<td>Rosemary Foundation Travel Grant</td>
<td>$15,000</td>
<td>$15,000</td>
</tr>
<tr>
<td>Alzheimer’s Australia Dementia Research Foundation Part Fellowship</td>
<td>$30,000 Per Annum for 3 years</td>
<td>$270,000</td>
</tr>
<tr>
<td>The Rhonda Trengove Dementia Awareness Research Grant</td>
<td>$30,000 Per Annum for 3 years</td>
<td>$90,000</td>
</tr>
<tr>
<td>The Hazel Hawke Research Grant in Dementia Care</td>
<td>$30,000 Per Annum for 3 years</td>
<td>$90,000</td>
</tr>
<tr>
<td>The Hiley-Allars 2012 Award</td>
<td>$30,000 Per Annum for 3 years</td>
<td>$90,000</td>
</tr>
<tr>
<td>The Commonwealth Bank Community Seeds Grant</td>
<td>$30,000 Per Annum for 3 years</td>
<td>$90,000</td>
</tr>
<tr>
<td>Alzheimer’s Australia Dementia Research Foundation Part Fellowship</td>
<td>$30,000 Per Annum for 3 years</td>
<td>$90,000</td>
</tr>
<tr>
<td>Alzheimer’s Australia Dementia Research Foundation Part Fellowship</td>
<td>$30,000 Per Annum for 3 years</td>
<td>$90,000</td>
</tr>
<tr>
<td>Alzheimer’s Australia Dementia Research Foundation Part Fellowship</td>
<td>$30,000 Per Annum for 3 years</td>
<td>$90,000</td>
</tr>
<tr>
<td>Alzheimer’s Australia Dementia Research Foundation PhD ‘Top Up’ Scholarships (x4)</td>
<td>$7,500 Per Annum for 2 years</td>
<td>$60,000</td>
</tr>
<tr>
<td><strong>Total value of program</strong></td>
<td><strong>$1,785,000.00</strong></td>
<td></td>
</tr>
</tbody>
</table>

* The Alzheimer’s Australia Victoria Research Foundation Awards share a common application process with the Dementia Grants Program, but are subject to eligibility criteria and assessment processes determined by the Alzheimer’s Australia Victoria Board. These awards are not formally a part of the Alzheimer’s Australia Dementia Research Foundation Dementia Grants Program, and are not listed on the Australian Competitive Grants Register.
THANK YOU FOR YOUR SUPPORT

The Foundation extends their special thanks to the following entities for their support:
Alzheimer’s Australia National
The Alzheimer’s Australia State and Territory Organisations
The Consumer Dementia Research Network

We would also like to express our gratitude to the following entities for their generous financial support:
Buxton Group and the Epsilon Research Fund
Resthaven Incorporated
The Rosemary Foundation for Memory Support Inc
The Sylvia and Charles Viertel Foundation
The Brookvale Rotary Club, Sydney
Grill’d Pty
Commonwealth Bank of Australia
Orange Ex-Services Club Limited
Simson Greeting Cards
Orange City Council
Sullair Australia P/L
Duggan Foundation
Friday Craft Group-Willow Glen Retirement Village
B’rai B’rith Foundation
Macquarie Group
Australian Institute Management NSW & ACT Training
Sunshine Coast ACAT
Australian Institute of Management
Business Chicks
Birchall Family Foundation Trust
Wilgarning Trust
The Forget Me Not Girls

Our thanks goes out to our payroll partners and their employees for their continued generous payroll giving:
Veda Advantage
Alcatel Lucent
ANZ Banking Group Ltd.
Dunn & Bradstreet
Suzanne Grae Corporation Pty Ltd
Travelex Ltd
BHP Billiton

We would also like to express our gratitude to the following individuals for their generous financial support:
Susan T King
Caron and John Boles
Dorothy Kimmorley
R S Macnaughtan
Joyce Tshe
Brendan Collins
John McCabe
Fiona E Winning
Ron Allars
Lorraine Allars
Margaret Stanger
Hazel Hiley
Mal Hiley
Yvonne Harrison
Christine Robbards
Graham Hiley
Libby Day
Chris Turner
Nic Trengove
Graham Trengove
Britt Barlow
Jaye Trengove
Todd Trengove
Dorothy Howse
Katerina Schielke
Bruce C Turner
B Nowak Karminski
Martin Jujou
Mark V Rider
Grant Spurr
Frances Kinghome
Kevin Wright
Mary Spencer
Kyylie Zhang
Francesco Sgro
Jane Peden
Margaret Mary Kitching
David Young
Rowan E Newton
A V Panuccio
Lesley Kelleher
Mr David Reckenberg
Brad & Anne Matthews
BS Brown
Fiona Winning
Leighan Kerr
Malcolm Elliott
Maurice Lichter
L. M. Lenny
Maxine Di Santo
Dr Janice Fairchild
D. H. Byrne
V. M. Urich

Brian Joseph Kelly
Kevin Condon Kelly
Peter Kelly
Joanna L Shulman
Owen W Staines
Margaret Robertson
Gregory W Hanson
Michelle A Roberts
We owe a big thank you to the following individuals:

Amy Dobos
Dr. Muireann Irish
Sue Pieters-Hawke
Dr Chris Hatherly
Sophie Pieters-Hawke
Andrea Britz
Tess Paul
Annabelle Boyd-Jones
Dr Adrienne Withall
Katherine Bowditch
A/Prof Olivier Piguet
Pavithra Amadoruge
Dr. Nady Brady
A/Prof Michael Valenzuela
Dr. Shayne Bellingham
Dr. Amee Baird
Scott Crouch
Dr. Zoe Terpening
Prof. Glynda Kinsella

We thank the following individuals for their time in assisting our Scientific and Medical Panel by externally assessing grant application:

Dr Anthony J Hannan
Prof Fran McInerney
Dr Jean Tinney
A/P Christine Toye
Prof Deborah Parker
Prof Nancy Pachana
Prof Perminder Sachdev
Prof Glynda Kinsella
Prof Mary Luszsz
Prof Daniel O’Connor
Dr Amee Baird
Prof Keith Hill
Prof Leon Flicker
Prof John Wade
Dr Veer Gupta
Dr Miranda Rose
A/Prof Olivier Piguet
Dr Lisa Keay
A/Prof Vijaya Sundararajan
Prof Brian Draper
Dr Dina Logiudice
Prof Gerald Muench
Dr Giuseppe Verdile
Dr. Toby Cumming
Mr Greg Mundy

Prof Stephen Gibson
Prof Daniel O’Connor
Prof Gerard Byrne
Prof Andrew McLachlan
Prof Andrew Robinson
Dr Ronald Sinclair
Prof Elizabeth Beattie
Dr Francis Corrigan
Dr Emma Thornton
A/Prof Deborah Graham
Prof Marie Cooke
Dr Claire Goldsbury
A/Prof Tracie Dickson
Prof Colin Masters
Prof Peter R Schofield
A/Prof Gerard Byrne
Dr. Louise Waite
A/Prof Christine Neville
Prof Deb Parker
A/Prof Kay Cox

Photographs supplied by the researchers, fundraisers and Resthaven Inc.

Images supplied by Shutterstock Inc, 2003
FINANCIAL REPORT

Alzheimer’s Australia Dementia Research Foundation Ltd.
ABN 79 081 407 534
Financial Report

For the year ending 30 June 2012

Financial information was extracted from the audited financial statements of Alzheimer’s Australia Dementia Research Foundation Ltd., for the year ending 30 June 2012 and is included here for information purposes only.

A full copy of Financial Statements, including Notes to the Financial Statements and the Audit Opinions, can be obtained free of charge on request from:

Alzheimer’s Australia Dementia Research Foundation Ltd.
1 Frewin Place
Scullin ACT 2614
Independent auditor’s report to the members of Alzheimer’s Australia Dementia Research Foundation Ltd

Report on the financial report

We have audited the accompanying financial report of Alzheimer’s Australia Dementia Research Foundation Ltd (the entity), which comprises the balance sheet as at 30 June 2012, the statement of comprehensive income, statement of changes in equity and statement of cash flows for the year ended on that date, a summary of significant accounting policies, other explanatory notes and the directors’ declaration.

Directors’ responsibility for the financial report

The directors of the entity are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards – Reduced Disclosure Requirements and the Corporations Act 2001 and for such internal control as the directors determine is necessary to enable the preparation of the financial report that is free from material misstatement, whether due to fraud or error.

Auditor’s responsibility

Our responsibility is to express an opinion on the financial report based on our audit. We conducted our audit in accordance with Australian Auditing Standards. These Auditing Standards require that we comply with relevant ethical requirements relating to audit engagements and plan and perform the audit to obtain reasonable assurance whether the financial report is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial report. The procedures selected depend on the auditor’s judgement, including the assessment of the risks of material misstatement of the financial report, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity’s preparation and fair presentation of the financial report in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the directors, as well as evaluating the overall presentation of the financial report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.
Independent auditor’s report to the members of Alzheimer’s Australia Dementia Research Foundation Ltd (Continued)

Independence

In conducting our audit, we have complied with the independence requirements of the Corporations Act 2001.

Auditor’s opinion

In our opinion the financial report of Alzheimer’s Australia Dementia Research Foundation Ltd is in accordance with the Corporations Act 2001, including:

(a) giving a true and fair view of the consolidated entity’s financial position as at 30 June 2012 and of its performance for the year ended on that date; and

(b) complying with Australian Accounting Standards – Reduced Disclosure Requirements and the Corporations Regulations 2001.

PricewaterhouseCoopers

[Signature]

Shane Bellechambers
Partner

Canberra
18 September 2012
**ALZHEIMER’S AUSTRALIA DEMENTIA RESEARCH FOUNDATION LTD**  
**ABN 79 081 407 534**

**STATEMENT OF COMPREHENSIVE INCOME FOR THE YEAR ENDED 30 JUNE 2012**

<table>
<thead>
<tr>
<th>Note</th>
<th>Description</th>
<th>2012 $</th>
<th>2011 $</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Revenue</td>
<td>1,179,562</td>
<td>738,339</td>
</tr>
<tr>
<td>3</td>
<td>Employee benefits expense</td>
<td>(64,864)</td>
<td>(35,253)</td>
</tr>
<tr>
<td>3</td>
<td>Grants issued</td>
<td>(423,578)</td>
<td>(499,168)</td>
</tr>
<tr>
<td></td>
<td>Other expenses</td>
<td>(85,263)</td>
<td>(29,417)</td>
</tr>
<tr>
<td></td>
<td>Profit for the year</td>
<td>605,857</td>
<td>174,501</td>
</tr>
<tr>
<td></td>
<td>Other comprehensive income</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Total comprehensive income for the year</td>
<td>605,857</td>
<td>174,500</td>
</tr>
</tbody>
</table>
## Statement of Financial Position as at 30 June 2012

<table>
<thead>
<tr>
<th></th>
<th>Note</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>$</td>
<td>$</td>
</tr>
<tr>
<td><strong>ASSETS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CURRENT ASSETS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>4</td>
<td>3,763,134</td>
<td>3,103,648</td>
</tr>
<tr>
<td>Trade and other receivables</td>
<td>5</td>
<td>111,889</td>
<td>61,132</td>
</tr>
<tr>
<td><strong>TOTAL CURRENT ASSETS</strong></td>
<td></td>
<td>3,875,023</td>
<td>3,164,780</td>
</tr>
<tr>
<td>NON-CURRENT ASSETS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Financial assets</td>
<td>6</td>
<td>610,720</td>
<td>675,541</td>
</tr>
<tr>
<td><strong>TOTAL NON-CURRENT ASSETS</strong></td>
<td></td>
<td>610,720</td>
<td>675,541</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td></td>
<td>4,485,743</td>
<td>3,840,321</td>
</tr>
<tr>
<td><strong>LIABILITIES</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CURRENT LIABILITIES</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trade and other payables</td>
<td>7</td>
<td>4,536</td>
<td>24,986</td>
</tr>
<tr>
<td>Other current liabilities</td>
<td>8</td>
<td>60,570</td>
<td>555</td>
</tr>
<tr>
<td><strong>TOTAL CURRENT LIABILITIES</strong></td>
<td></td>
<td>65,106</td>
<td>25,541</td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES</strong></td>
<td></td>
<td>65,106</td>
<td>25,541</td>
</tr>
<tr>
<td><strong>NET ASSETS</strong></td>
<td></td>
<td>4,420,637</td>
<td>3,814,780</td>
</tr>
<tr>
<td><strong>EQUITY</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retained Earnings</td>
<td></td>
<td>4,420,637</td>
<td>3,814,780</td>
</tr>
<tr>
<td><strong>TOTAL EQUITY</strong></td>
<td></td>
<td>4,420,637</td>
<td>3,814,780</td>
</tr>
</tbody>
</table>
DIRECTORS’ DECLARATION

The directors of the entity declare that:

1. The financial statements and notes, as set out on pages 6 to 19 are in accordance with the Corporations Act 2001, and:
   a. comply with Australian Accounting Standards; and
   b. give a true and fair view of the financial position as at 30 June 2012 and of the performance for the year ended on that date of the entity;

2. In the directors’ opinion there are reasonable grounds to believe that the entity will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors.

Sign

Name

Date

17/9/12

Sign

Name

Date

17/9/12